Analyst Summary
- An independent health service study of NanoVibronix’s UroShield device was published in The Australian and New Zealand Continence Journal.
- The study demonstrates UroShield’s effectiveness in preventing catheter-associated urinary tract infections (CAUTIs) and catheter blockages.
- Patients using UroShield experienced significant reductions: 86% in UTI incidence, 70% in catheter blockages, 82.8% less bladder irrigations, and 52.3% less catheter changes.
- Clinicians reported improved overall catheter comfort and a reduction in the need for catheter-related interventions.
- The study also indicated that UroShield required less nursing time, easing workload demands and resulting in measurable cost savings for healthcare providers, with a 63.5% reduction in resource cost over 5 months.
- NanoVibronix’s CEO, Brian Murphy, highlighted the benefits of UroShield in enhancing patient care and minimizing catheter complications.